CHMP positive recommendation for Eliquis (apixaban) to treat venous thromboembolism (VTE) and prevention of recurrent VTE in children – BMS + Pfizer

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Eliquis (apixaban).

The marketing authorisation holder for this medicinal product is Bristol-Myers Squibb/Pfizer EEIG. The CHMP adopted an extension to the existing indication to include treatment of venous thromboembolism (VTE) and prevention of recurrent VTE in children, associated with the addition of new pharmaceutical forms and new strengths (0.15 mg granules in capsules for opening, as well as 0.5, 1.5 and 2 mg coated granules in sachet).